Yes. Urine drug testing ordered as part of a documented pain management treatment plan is a covered benefit under Medicare, Medicaid, and most commercial insurance plans. Results Diagnostics handles all billing directly. Your clinic pays nothing and manages no claims.
Pain management is one of the most heavily scrutinized specialties in medicine. DEA audits, state medical board investigations, and payer audits are routine. The standard of care — and increasingly the legal standard — requires documented, defensible urine drug testing for every patient on a controlled substance regimen.
Immunoassay point-of-care cup tests were not designed for this environment. They screen for drug classes, not specific compounds. They cannot confirm whether a patient is actually taking their prescribed medication versus diverting it. They generate false positives on common over-the-counter drugs. And they do not hold up under audit.
Results Diagnostics uses liquid chromatography-mass spectrometry (LCMS) — the gold standard methodology used by forensic laboratories, medical review officers, and federal drug testing programs. Every result identifies the specific compound, quantifies the amount present, and is documented with a full chain of custody. When a DEA auditor or payer asks for documentation of your drug monitoring program, LCMS results hold up. Cup tests do not.
Confirms patients are taking their prescribed medications — opioids, benzodiazepines, muscle relaxants, and other controlled substances — at therapeutic levels. Detects diversion. Documents compliance. Protects your practice.
Every major opioid identified to the specific compound: oxycodone, hydrocodone, morphine, codeine, hydromorphone, oxymorphone, buprenorphine, tramadol, fentanyl, norfentanyl, acetylfentanyl, carfentanil, and more. The most comprehensive opioid panel available.
Fentanyl is now present in the illicit drug supply in every major market. Patients on legitimate opioid regimens may be unknowingly exposed. Our panel detects fentanyl and its analogues separately from prescribed medications — giving your clinical team the full picture.
Standard immunoassay screens routinely miss designer benzodiazepines increasingly found in the illicit supply — clonazolam, etizolam, flualprazolam, and others. We identify all 11 benzodiazepines by name. Critical for patients on multi-drug regimens.
Carisoprodol, cyclobenzaprine, methocarbamol — confirms adherence and detects misuse in patients on combination pain management protocols.
For patients on ADHD medications concurrent with pain management — amphetamines, methylphenidate, and related compounds confirmed to the specific molecule.
Detects alcohol use up to 80 hours after consumption. Essential for pain clinics with zero-tolerance alcohol policies or patients where alcohol interaction with opioids creates clinical risk.
Increasingly prescribed for pain management, increasingly misused. Both detected and quantified separately.
Xylazine is appearing in the illicit opioid supply in every major market. It is not detectable on standard immunoassay screens. Our panel detects it. If your patients are in a market where fentanyl is present — which is every major market — Xylazine is in the supply chain.
Nothing. Urine drug testing is a covered benefit under Medicare, Medicaid, and most commercial insurance plans when ordered as part of a documented pain management treatment plan. Results Diagnostics bills the patient’s insurance directly. Your clinic does not receive an invoice, manage claims, or front any costs.
| Service | Cost to Clinic |
|---|---|
| LCMS testing and processing | $0 |
| Collection supplies and requisition forms | $0 |
| Results delivery and portal access | $0 |
| Dedicated account representative | $0 |
| Monthly utilization report | $0 |
| Long-term contract | Not required |
The regulatory environment for pain management has tightened significantly. The DEA, state medical boards, and Medicaid managed care organizations are actively auditing pain clinics for documentation of controlled substance monitoring. Payers are denying claims and clawing back reimbursements from clinics that cannot produce defensible drug testing records.
Immunoassay cup tests are not audit-defensible. They cannot identify specific compounds, cannot distinguish between substances in the same drug class, and carry a false positive rate that creates clinical and legal exposure.
LCMS results are confirmatory by definition. Every positive is identified to the specific compound, quantified, and documented with a full chain of custody. They hold up under DEA audit, payer review, and legal scrutiny. For a pain management clinic, the difference between cup tests and LCMS is the difference between a documentation gap and a defensible record.
Day 0: Sign the Lab Services Agreement — 30-day termination clause, no lock-in.
Days 1–2: We deliver your supply kit — collection cups, chain of custody forms, custom requisition forms printed with your clinic name.
Days 3–5: Kickoff call — confirm panel, pickup schedule, results delivery. 15 minutes.
Days 7–10: In-person staff training at your clinic. 30 minutes. Every staff member leaves with a direct number for your account representative.
Day 30: First monthly utilization report — your clinic’s data, panel utilization, and positivity trends summarized for your clinical and compliance team.
Ongoing: Quarterly in-person check-ins. Proactive supply management. Direct line to our team — not a call center.
Standard results are returned within 24 hours of specimen receipt. Critical results — including unexpected positives for fentanyl, Xylazine, or undisclosed substances — are called directly to the ordering clinician the same day.
No. Our Lab Services Agreement includes a 30-day termination clause. We earn your business every month.
Results Diagnostics is enrolled as a Medicare provider. We bill Medicare directly for all covered testing using the appropriate CPT codes for definitive drug testing. Your clinic is not involved in the billing process.
We bill definitive drug testing CPT codes (G0480–G0483) based on drug class and number of analytes tested — the highest-reimbursing category of urine drug testing. Presumptive testing codes (G0477–G0479) apply to immunoassay screens. LCMS always qualifies for definitive coding.
Yes. LCMS results provide specific compound identification, quantification, and chain of custody documentation — the three elements regulators and auditors look for when reviewing controlled substance monitoring programs. Cup tests provide none of these.
Local presence, faster turnaround, and a dedicated account representative who knows your clinic. We are not a national reference lab with a call center. We are a local lab that competes on service — and we back that up with a 30-day out clause.
Results Diagnostics is CLIA-certified (CLIA # 29D2310339) and COLA-accredited (COLA # 33493). COLA accreditation requires an on-site inspection and ongoing compliance review — a voluntary, peer-reviewed standard that goes beyond the federal CLIA baseline.
Contact our team.
Phone: 702-830-5100
Email: info@results-dx.com
Address: 5580 S. Fort Apache Rd, Unit 120, Las Vegas, NV 89148
Results Diagnostics LLC | CLIA # 29D2310339 | NPI # 1063253094